Vishal Manchanda, Pharma Analyst at Systematix Group, stated that Sun Pharmaceuticals stands to gain significantly from its recent acquisition of Checkpoint Therapeutics, as it provides access to the PD-L1 inhibitor, cosibelimab. This skin cancer treatment presents a substantial market opportunity.
